Short Interest in Revolution Medicines, Inc. (NASDAQ:RVMDW) Declines By 29.3%

Revolution Medicines, Inc. (NASDAQ:RVMDW) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 1,373 shares, a decline of 29.3% from the November 30th total of 1,943 shares. Based on an average daily trading volume, of 28,634 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 28,634 shares, the days-to-cover ratio is presently 0.0 days.

Revolution Medicines Stock Performance

Revolution Medicines stock traded up $0.05 during midday trading on Wednesday, reaching $0.94. 102,830 shares of the stock traded hands, compared to its average volume of 30,571. The company has a 50-day simple moving average of $0.64 and a two-hundred day simple moving average of $0.39. Revolution Medicines has a 12-month low of $0.03 and a 12-month high of $1.08.

About Revolution Medicines

Revolution Medicines (NASDAQ:RVMDW) is a clinical-stage oncology company focused on discovering and developing small-molecule therapies that target the RAS signaling pathway. The company’s scientific approach centers on designing molecules that selectively inhibit mutant RAS proteins and key regulators of RAS-driven cancers, with the goal of addressing tumor types that have historically been resistant to targeted therapies.

Revolution Medicines has advanced multiple pipeline candidates into clinical trials, including RMC-4630, a selective SHP2 inhibitor, and RMC-6236, an oral pan-RAS inhibitor designed to block signaling from multiple RAS mutants.